ANKE BIO(SZ:300009)2022-12-08 08:52Financial Performance - In the first three quarters of 2015, the overall sales growth slowed down, with a 45% increase in chemical drugs in the first half, but stagnation in the third quarter [2] - Biological products saw a growth of approximately 30% in the third quarter, with over 35% growth in the first three quarters [4] - Interferon experienced slight growth in the third quarter, with over 10% growth in the first three quarters [4] - Traditional Chinese medicine (TCM) grew over 30% in the third quarter and over 20% in the first three quarters [4] - Chemical drugs remained flat in the third quarter but had over 30% growth in the first three quarters [4] Market Dynamics - The slowdown in chemical drug sales in the third quarter was attributed to inventory adjustments due to GSP certification, increased tax control policies, and changes in the OTC market [4] - In October, chemical drug sales began to recover rapidly [5] - The company has been expanding its market presence through marketing reforms and product updates, leading to faster growth in TCM [5] Product Development - The company is focusing on CAR-T cell therapy and gene testing as part of its precision medicine strategy, with ongoing clinical trials [6] - The collaboration with Boshengji Company in CAR-T cell therapy is showing promising clinical results [6] - The company is also involved in the development of health products, including mouthwash and facial masks, with plans to expand sales channels [5] Future Outlook - The company aims for both external growth through market expansion and internal growth by leveraging product advantages to achieve sustained rapid growth [7]